ASX - By Stock
|
ATX |
Re:
Ann: Becoming a substantial holder
|
|
Zeds
|
14 |
4.7K |
0 |
18/11/21 |
18/11/21 |
ASX - By Stock
|
14
|
4.7K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Annual General Meeting to be Held 27 August 2021
|
|
Zeds
|
7 |
2.9K |
5 |
28/06/21 |
28/06/21 |
ASX - By Stock
|
7
|
2.9K
|
5
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Annual General Meeting to be Held 27 August 2021
|
|
Zeds
|
7 |
2.9K |
2 |
28/06/21 |
28/06/21 |
ASX - By Stock
|
7
|
2.9K
|
2
|
|
ASX - By Stock
|
ATX |
Re:
Ann: AMP945 Improves Survival in Pacnreatic Cancer Model
|
|
Zeds
|
49 |
15K |
5 |
28/06/21 |
28/06/21 |
ASX - By Stock
|
49
|
15K
|
5
|
|
ASX - By Stock
|
ATX |
Re:
Ann: AMP945 Improves Survival in Pacnreatic Cancer Model
|
|
Zeds
|
49 |
15K |
8 |
23/06/21 |
23/06/21 |
ASX - By Stock
|
49
|
15K
|
8
|
|
ASX - By Stock
|
ATX |
Re:
Ann: AMP945 Improves Survival in Pacnreatic Cancer Model
|
|
Zeds
|
49 |
15K |
9 |
02/06/21 |
02/06/21 |
ASX - By Stock
|
49
|
15K
|
9
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Amplia Announces $3.8m Share Placement
|
|
Zeds
|
3 |
1.2K |
1 |
04/05/21 |
04/05/21 |
ASX - By Stock
|
3
|
1.2K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: ATX FAK Inhibitors Reduce Fibrosis in Animal Model of NASH
|
|
Zeds
|
16 |
4.7K |
1 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
16
|
4.7K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Initial Director's Interest Notice - Jane Bell
|
|
Zeds
|
2 |
1.2K |
6 |
28/04/21 |
28/04/21 |
ASX - By Stock
|
2
|
1.2K
|
6
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Preclinical Data Support Developmnt AMP945 Pancreatic Cancer
|
|
Zeds
|
5 |
1.8K |
5 |
28/04/21 |
28/04/21 |
ASX - By Stock
|
5
|
1.8K
|
5
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Amplia and Garvan Institute Enter Collaboration Agreement
|
|
Zeds
|
11 |
3.2K |
14 |
18/03/21 |
18/03/21 |
ASX - By Stock
|
11
|
3.2K
|
14
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Amplia Completes Single Dose Study of AMP945
|
|
Zeds
|
10 |
2.6K |
7 |
17/03/21 |
17/03/21 |
ASX - By Stock
|
10
|
2.6K
|
7
|
|
ASX - By Stock
|
AGH |
Re:
Chartiness...
|
|
Zeds
|
12 |
9.5K |
2 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
12
|
9.5K
|
2
|
|
ASX - By Stock
|
AGH |
Re:
Ann: Althea Completes First Shipment Of Products To Grow Pharma
|
|
Zeds
|
4 |
2.6K |
1 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
4
|
2.6K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Investor Update - February 2021
|
|
Zeds
|
9 |
3.4K |
5 |
12/02/21 |
12/02/21 |
ASX - By Stock
|
9
|
3.4K
|
5
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities and Cashflow Reports - Dec 2020 Qtr
|
|
Zeds
|
10 |
2.9K |
3 |
04/02/21 |
04/02/21 |
ASX - By Stock
|
10
|
2.9K
|
3
|
|
ASX - By Stock
|
AGH |
Re:
Ann: Appendix 4C - quarterly
|
|
Zeds
|
20 |
7.3K |
3 |
01/02/21 |
01/02/21 |
ASX - By Stock
|
20
|
7.3K
|
3
|
|
ASX - By Stock
|
AGH |
Re:
Ann: Appendix 4C - quarterly
|
|
Zeds
|
20 |
7.3K |
3 |
01/02/21 |
01/02/21 |
ASX - By Stock
|
20
|
7.3K
|
3
|
|
ASX - By Stock
|
AGH |
Re:
Ann: December Sales Exceed $1.19M With 90% Monthly Growth in UK
|
|
Zeds
|
12 |
6.7K |
4 |
15/01/21 |
15/01/21 |
ASX - By Stock
|
12
|
6.7K
|
4
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Response to ASX Price Query
|
|
Zeds
|
8 |
2.5K |
3 |
20/10/20 |
20/10/20 |
ASX - By Stock
|
8
|
2.5K
|
3
|
|
ASX - By Stock
|
ATX |
Re:
Ann: First Human Dose in Phase 1 Clinical Trial of AMP945
|
|
Zeds
|
63 |
18K |
1 |
20/10/20 |
20/10/20 |
ASX - By Stock
|
63
|
18K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: First Human Dose in Phase 1 Clinical Trial of AMP945
|
|
Zeds
|
63 |
18K |
5 |
19/10/20 |
19/10/20 |
ASX - By Stock
|
63
|
18K
|
5
|
|
ASX - By Stock
|
ATX |
Re:
Ann: First Human Dose in Phase 1 Clinical Trial of AMP945
|
|
Zeds
|
63 |
18K |
5 |
14/10/20 |
14/10/20 |
ASX - By Stock
|
63
|
18K
|
5
|
|